Nuwellis, Inc. (NASDAQ:NUWE) Short Interest Update
by Doug Wharley · The Cerbat GemNuwellis, Inc. (NASDAQ:NUWE – Get Free Report) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 8,554 shares, a decrease of 83.3% from the November 30th total of 51,367 shares. Currently, 0.6% of the shares of the company are short sold. Based on an average daily volume of 55,808 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 55,808 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.6% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on NUWE. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuwellis in a research note on Monday. Wall Street Zen cut shares of Nuwellis from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.
Get Our Latest Research Report on NUWE
Nuwellis Price Performance
Shares of NUWE stock traded up $0.09 during midday trading on Thursday, hitting $2.14. The company had a trading volume of 6,929 shares, compared to its average volume of 43,276. The stock has a market cap of $3.54 million, a price-to-earnings ratio of -0.02 and a beta of -0.17. The company’s 50 day simple moving average is $2.63 and its 200 day simple moving average is $5.63. Nuwellis has a 52-week low of $2.02 and a 52-week high of $70.14.
Nuwellis (NASDAQ:NUWE – Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of ($17.22) by $17.78. The firm had revenue of $2.22 million during the quarter, compared to the consensus estimate of $2.50 million. Nuwellis had a negative return on equity of 1,367.63% and a negative net margin of 202.83%. Analysts anticipate that Nuwellis will post -8.17 EPS for the current year.
About Nuwellis
Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.
The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.